Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Active not recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 141Breast Neoplasms 10Neoplasm Metastasis 8Neoplasms 5Bulbo-Spinal Atrophy, X-Linked 5Triple Negative Breast Neoplasms 4Salivary Gland Neoplasms 3Prostate Adenocarcinoma 2Osteoporosis 2Lower Urinary Tract Symptoms 2Hirsutism 2Thrombocytosis 1Stage I Prostate Adenocarcinoma AJCC v7 1Stage I Prostate Adenocarcinoma 1Sexual Dysfunction, Physiological 1Recurrence 1Primary Myelofibrosis 1Primary Dysautonomias 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycystic Ovary Syndrome 1Pancreatic Neoplasms 1Paget Disease, Extramammary 1PSA Level Greater Than Two 1Ovarian Neoplasms 1Non-Muscle Invasive Bladder Urothelial Carcinoma 1Non-Muscle Invasive Bladder Neoplasms 1Non Castrate Metastatic Prostate Cancer 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1

Interventions

Magnetic Resonance Spectroscopy 5Radiosurgery 4luprolide acetate gel depot 3enzalutamide 3Radiotherapy 3Radiation 3Leuprolide 3Goserelin 3relugolix 2gallium 68 PSMA-11 2bicalutamide 2acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 2Triptorelin Pamoate 2Specimen Handling 2Proton Therapy 2Biopsy 2radium Ra 223 dichloride 1niraparib 1histrelin 1fluciclovine F-18 1flibanserin 1entinostat 1darolutamide 1atezolizumab 1apalutamide 1abiraterone 1X-Rays 1Watchful Waiting 1Surveys and Questionnaires 1Surgical Procedures, Operative 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Prostate Adenocarcinoma × bicalutamide × Clear all
NCT05050084 2026-05-04

Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial

NRG Oncology

Phase 3 Active not recruiting
2,050 enrolled
Genitourinary

Prostate Adenocarcinoma

NCT04943536 2026-02-27

BiolenRT

Alessa Therapeutics Inc.

Phase 1 Active not recruiting
20 enrolled
Genitourinary

Prostate Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡